Search results for "Systems medicine"

showing 10 items of 11 documents

Making sense of big data in health research: {T}owards an {EU} action plan

2016

Genome medicine 8(1), 71 (2016). doi:10.1186/s13073-016-0323-y

0301 basic medicineBiomedical ResearchDatabases FactualPREDICTIONComputer scienceBig data: Santé publique services médicaux & soins de santé [D22] [Sciences de la santé humaine]XXBioinformaticsBases de dadesSYSTEMS MEDICINE0302 clinical medicineINFORMATICSCultural diversityHealth careGenetics(clinical)030212 general & internal medicineGenetics (clinical)media_commonGenetics & HeredityExabyteCHALLENGESMacrodadesCANCER3. Good healthAction planMolecular MedicineErratumLife Sciences & BiomedicineMedical GeneticsOpinion: Public health health care sciences & services [D22] [Human health sciences]MedicinaInformation DisseminationMECHANISMS03 medical and health sciencesFUTUREJournal ArticleGeneticsmedia_common.cataloged_instanceHumansKNOWLEDGEEuropean UnionEuropean unionMolecular BiologyMedicinsk genetik0604 GeneticsScience & Technologybusiness.industryInformation DisseminationHealth Plan Implementation1103 Clinical SciencesCAREData scienceData sharing030104 developmental biologyUNDIAGNOSED DISEASES NETWORKbusiness
researchProduct

Comprehensive evaluation of coding region point mutations in microsatellite-unstable colorectal cancer

2018

Microsatellite instability (MSI) leads to accumulation of an excessive number of mutations in the genome, mostly small insertions and deletions. MSI colorectal cancers (CRCs), however, also contain more point mutations than microsatellite-stable (MSS) tumors, yet they have not been as comprehensively studied. To identify candidate driver genes affected by point mutations in MSI CRC, we ranked genes based on mutation significance while correcting for replication timing and gene expression utilizing an algorithm, MutSigCV. Somatic point mutation data from the exome kit-targeted area from 24 exome-sequenced sporadic MSI CRCs and respective normals, and 12 whole-genome-sequenced sporadic MSI CR…

0301 basic medicineMedicine (General)Candidate geneclinical evaluationgenetic identificationgenetic analysisQH426-470medicine.disease_causeChromatin Epigenetics Genomics & Functional Genomicswhole exome sequencingddc:590mutator genesingle nucleotide polymorphismddc:576.5Gene Regulatory NetworksExomeExome sequencingCancercancer cellGeneticsMutation1184 Genetics developmental biology physiology3. Good healthgenetic codesyöpägeenitpriority journalMolecular Medicinewild typepoint mutationSystems MedicineColorectal Neoplasmscongenital hereditary and neonatal diseases and abnormalitiesddc:025.063/5703122 Cancerscancer geneticsSingle-nucleotide polymorphismcolorectal cancerBiologygene frequencyta3111mikrosatelliititcolony formationR105W geneArticle03 medical and health sciencesR5-920Gene interactionReportGeneticsmedicineHumanscontrolled studyhumanneoplasmspaksusuolisyöpäPoint mutationgene interactionhuman celltumor-related geneMicrosatellite instabilityMolecular Sequence AnnotationSequence Analysis DNAmedicine.diseaseta3122digestive system diseaseshuman tissueSTK38L gene030104 developmental biologyvalidation processgene expressionSMARCB1 genemicrosatellite instability3111 Biomedicinegene replicationReports
researchProduct

A "systems medicine" approach to the study of non-alcoholic fatty liver disease

2016

a b s t r a c t The prevalence of fatty liver (steatosis) in the general population is rapidly increasing worldwide. The progress of knowledge in the physiopathology of fatty liver is based on the systems biology approach to studying the complex interactions among different physiological systems. Similarly, translational and clinical research should address the complex interplay between these systems impacting on fatty liver. The clinical needs drive the applications of systems medicine to re-define clinical phenotypes, assessing the multiple nature of disease susceptibility and progression (e.g. the definition of risk, prognosis, diag- nosis criteria, and new endpoints of clinical trials).…

0301 basic medicinePathologymedicine.medical_specialtyFatty liver; Medicine; NAFLD; NASH; Personalized; Systems medicine; Gastroenterology; HepatologySystems AnalysisSystems biologyPersonalizedPopulationDiseaseBioinformatics03 medical and health sciences0302 clinical medicineNon-alcoholic Fatty Liver DiseaseRisk FactorsInternal medicineFatty liverNAFLDFatty liver; Medicine; NAFLD; NASH; Personalized; Systems medicinemedicineHumansFatty liver; Medicine; NAFLD; NASH; Personalized; Systems medicine; Hepatology; GastroenterologyeducationFatty liver; Medicine; NAFLD; NASH; Personalized; Systems medicine; Disease Progression; Humans; Non-alcoholic Fatty Liver Disease; Phenotype; Risk Factors; Systems Biology; Systems Analysis; Medicine (all); Hepatology; Gastroenterologyeducation.field_of_studyHepatologybusiness.industrySystems BiologySettore MED/09 - MEDICINA INTERNAFatty liverGastroenterologyNASHHepatologymedicine.diseaseSystems medicineClinical trial030104 developmental biologyPhenotypeSystems medicineDisease ProgressionMedicine030211 gastroenterology & hepatologySteatosisbusiness
researchProduct

Transcription factor NRF2 as a therapeutic target for chronic diseases: a systems medicine approach

2018

Systems medicine has a mechanism-based rather than a symptom- or organ-based approach to disease and identifies therapeutic targets in a nonhypothesis-driven manner. In this work, we apply this to transcription factor nuclear factor (erythroid-derived 2)-like 2 (NRF2) by cross-validating its position in a protein-protein interaction network (the NRF2 interactome) functionally linked to cytoprotection in low-grade stress, chronic inflammation, metabolic alterations, and reactive oxygen species formation. Multiscale network analysis of these molecular profiles suggests alterations of NRF2 expression and activity as a common mechanism in a subnetwork of diseases (the NRF2 diseasome). This netw…

0301 basic medicineRMSystems AnalysisNF-E2-Related Factor 2MedicinaNF-KAPPA-BAnti-Inflammatory AgentsTYPE-2 DIABETES-MELLITUSGENE PROMOTER POLYMORPHISMDiseaseComputational biologyInteractomeenvironment and public healthGLYCOGEN-SYNTHASE KINASETUMOR-SUPPRESSOR PTENNRF203 medical and health sciencesDrug DiscoveryAnimalsHumansTherapeutic targetsMedicineMolecular Targeted TherapyBardoxolone methylPLACEBO-CONTROLLED PHASE-3PharmacologyMechanism (biology)Drug discoverybusiness.industryDrug RepositioningRChronic inflammationrespiratory systemHEME OXYGENASE 1PROTEIN-PROTEIN INTERACTION3. Good healthSystems medicineDrug repositioning030104 developmental biologyDrug developmentEXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITISChronic DiseaseSystems medicineMolecular MedicineFUMARIC-ACID ESTERSbusiness
researchProduct

Metabolic Pathway Analysis 2019: Systems (biology+medicine) : 12th-16th August 2019, Riga, Latvia

2019

:NATURAL SCIENCES::Biology [Research Subject Categories]Reconstituated Systems and Synthetc BiologyMethodologyFundamentals of metabolic network structureprimary and secondary metabolismMetabolicApplied metabolic systemsSystems MedicineSoftwareMathematical algorithms
researchProduct

Rationale, design and baseline characteristics of the MyoVasc study: A prospective cohort study investigating development and progression of heart fa…

2020

Abstract Background Heart failure (HF) is a poly-aetiological syndrome with large heterogeneity regarding clinical presentation, pathophysiology, clinical outcome and response to therapy. The MyoVasc study (NCT04064450) is an epidemiological cohort study investigating the development and progression of HF. Methods The primary objective of the study is (a) to improve the understanding of the pathomechanisms of HF across the full spectrum of clinical presentation, (b) to investigate the current clinical classifications of HF, and (c) to identify and characterize homogeneous subgroups regarding disease development using a systems-oriented approach. Worsening of HF, that is, the composite of tr…

AdultMalemedicine.medical_specialtyResponse to therapyEpidemiologyCohort StudiesmedicineHumansProspective StudiesIntensive care medicineProspective cohort studyAgedBiological Specimen BanksAged 80 and overHeart Failurebusiness.industryStroke VolumeMiddle Agedmedicine.diseaseSystems medicineBaseline characteristicsHeart failureFemalePresentation (obstetrics)Cardiology and Cardiovascular MedicinebusinessEuropean journal of preventive cardiology
researchProduct

Moving from the Oslerian paradigm to the postgenomic era: Are asthma and COPD outdated terms?

2016

In the majority of cases, asthma and chronic obstructive pulmonary disease (COPD) are two clearly distinct disease entities. However, in some patients there may be significant overlap between the two conditions. This constitutes an important area of concern because these patients are generally excluded from randomised controlled trials (mostly because of smoking history in the case of asthma or because of significant bronchodilator reversibility in the case of COPD). As a result, their pathobiology, prognosis and response to therapy are largely unknown. This may lead to suboptimal management and can limit the development of more personalised therapeutic options. Emerging genetic and molecul…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyPlacebo-controlled studyAlternative medicinePHENOTYPESAIRWAY DISEASEDiseasePLACEBO-CONTROLLED TRIALOBSTRUCTIVE PULMONARY-DISEASETHERAPYCOPD MechanismsDOUBLE-BLINDPulmonary Disease Chronic ObstructiveAsthma; COPD MechanismsTerminology as TopicmedicineHumansDiseasePrecision MedicineIntensive care medicineINDEXAsthmaCLUSTER-ANALYSISCOPDbusiness.industrySystems Biologymedicine.diseaseAsthmaLUNG-FUNCTIONSystems medicineEXACERBATIONSPhenotypePhysical therapyHealth educationPersonalized medicinebusinessThorax
researchProduct

Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B…

2016

Action Plan B3 of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA) focuses on the integrated care of chronic diseases. Area 5 (Care Pathways) was initiated using chronic respiratory diseases as a model. The chronic respiratory disease action plan includes (1) AIRWAYS integrated care pathways (ICPs), (2) the joint initiative between the Reference site MACVIA-LR (Contre les MAladies Chroniques pour un VIeillissement Actif) and ARIA (Allergic Rhinitis and its Impact on Asthma), (3) Commitments for Action to the European Innovation Partnership on Active and Healthy Ageing and the AIRWAYS ICPs network. It is deployed in collaboration with the World Health Organizatio…

Pulmons -- Malalties obstructivesVeterinary medicineAllergyPublished ErratumLANGUEDOC-ROUSSILLONAllergyRespiratory Medicine and Allergy[SDV]Life Sciences [q-bio]Aparell respiratori -- MalaltiesOPERATIONAL DEFINITIONAlternative medicineReviewChronic respiratory diseasesGLOBAL ALLIANCESYSTEMS MEDICINE0302 clinical medicineMedicine and Health SciencesImmunology and AllergyMACVIA030212 general & internal medicineAIRWAYS ICPLungmedicin och allergiEIP on AHA; European Innovation Partnership on Active and Healthy Ageing; Chronic respiratory diseases; AIRWAYS ICPs; MACVIA; ARIA; Scaling upGINA STRATEGYAIRWAYSUPDATE ARIA 2008Scaling upRespiratory disease:Outras Ciências Agrárias [Ciências Agrárias]3. Good healthChronic respiratory diseaseALLERGIC RHINITISICPsAIRWAYS ICPsGeneral partnershipAction planErratumLife Sciences & BiomedicineAIRWAYS ICPs; ARIA; Chronic respiratory diseases; EIP on AHA; European Innovation Partnership on Active and Healthy Ageing; MACVIA; Scaling upPulmonary and Respiratory Medicinemedicine.medical_specialtyEIP on AHAAIRWAYS ICPs; ARIA; Chronic respiratory diseases; EIP on AHA; European Innovation Partnership on Active and Healthy Ageing; MACVIA; Scaling up; Immunology and AllergyEmerging technologiesImmunologyREFERENCE SITESocio-culturalePredictive medicine03 medical and health sciencesEuropean Innovation Partnership on Active and Healthy AgeingNursingCritical success factorJournal Articlemedicineddc:610Science & TechnologyARIAbusiness.industrySettore MED/09 - MEDICINA INTERNAAIRWAYS-ICPSmedicine.diseaseIntegrated careAlliance030228 respiratory systemCiências Agrárias::Outras Ciências Agrárias3121 General medicine internal medicine and other clinical medicineFamily medicineImmunologyHealthy ageingbusinessSEVERE ASTHMA
researchProduct

General Systems Theory and Systems Biology

2015

We should not imagine that Systems Biology was born yesterday, indeed von Bertalanffy was a well-known supporter of the need to approach biological entities from the notion of a system. There is a tradition, dating back to early times, calling for the study of living things as a whole. Holism is no stranger to modern Systems Biology and, likewise, von Bertalanffy supported the quantitative study of the whole from the interaction of its parts.

Systems medicineMathematical and theoretical biologySystems theorySystems biologyHolismSociologyComplex systems biologyYesterdayBiological organisationEpistemology
researchProduct

Cancer: Clinical Background and Key Challenges

2011

This chapter is aimed at a wide audience ranging from biologists to medical students and cancer specialists. It provides a comprehensive overview of systems approaches to the pathology and treatment of cancer. In particular, it addresses diagnosis and therapy by interconnecting various aspects of cancer at both the molecular and clinical level, and contrasts the unifying features of malignancies with the daunting diversity of cancer types, stages, and evolutionary processes during treatment. The importance is emphasized of both prevention and innovative treatments in reducing the cancer burden, and of early detection as the link between these two major areas. It sets the stage for analysis …

Systems medicinebusiness.industrySystems biologyEarly detectionMedicineResearch needsSystems approachesBioinformaticsbusinessData scienceGrading (tumors)Signalling pathwaysImaging data
researchProduct